ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Preserflo microshunt outcomes in pigmentary glaucoma: a propensity score-matched comparison with primary open-angle glaucoma.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the outcomes of Preserflo MicroShunt (PMS) implantation in pigmentary glaucoma (PG) and compare them with a matched primary open-angle glaucoma (POAG) cohort. PATIENTS AND
methodsThis retrospective study included consecutive patients with PG undergoing PMS implantation between 2021 and 2025 at a single tertiary centre. A 1:2 propensity score-matched POAG control group was created based on demographic and clinical baseline characteristics. The primary outcome was surgical success at 2 years, defined as ≥ 20% IOP reduction and IOP ≤ 18 mmHg without hypotony-related complications. Secondary outcomes included stricter success criteria, IOP reduction, medication use, revisions, and complications.
resultsThirty-one PG patients were matched to 62 POAG patients. Median follow-up was 28 and 32 months, respectively. PMS implantation resulted in significant and sustained IOP reduction in both groups (all p < 0.01), with no significant differences between PG and POAG at any time point. Median IOP at 2 years was 14 mmHg in both groups. IOP-lowering agents decreased to a median of 0 in both groups, with most patients remaining medication-free. Complete success at 2 years was 61% in PG and 49% in POAG (p = 0.35). Bleb revisions were required in 45% and 52%. Outcomes across stricter success criteria and complications were not significantly different.
conclusionsPMS implantation in PG was not associated with significantly different efficacy, safety and revision burden compared with POAG. The distinct pathophysiology of PG does not appear to adversely affect surgical outcomes, supporting the PMS as a viable treatment option in this population.
Indexed as
Identifiers
42603176What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.